FY2025 · ended Dec 31, 2025 · Revenue $517.14M, +16.0% YoY · Filed Feb 26, 2026
Veracyte, Inc. (VCYT) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $517.1 million and net income of $66.4 million. Free cash flow was $126.6 million. As of Sep 30, 2026 it held $250.1 million in cash and investments and $40.7 million in total debt.
Revenue (TTM)
$581.78M
+17.5% vs year-ago TTM
Net income (TTM)
$126.85M
+318.4% vs year-ago TTM
Operating cash flow (TTM)
$173.88M
+60.6% vs year-ago TTM
Free cash flow (TTM)
$161.95M
+64.9% vs year-ago TTM
EPS (TTM)
$1.54
+307.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
79.46M
+1.9% vs prior year
Net cash
$209.40M
as of Sep 30, 2026
Operating margin
17.1%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- VCYT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1384101
- Former names
- CALDEROME INC (until Feb 27, 2008)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M | $219.5M |
| Operating income | $57.8M | $16.1M | -$85.8M | -$41.1M | -$81.9M |
| Net income | $66.4M | $24.1M | -$74.4M | -$36.6M | -$75.6M |
| Diluted EPS | $0.82 | $0.31 | -$1.02 | -$0.51 | -$1.11 |
| Operating cash flow | $136.3M | $75.1M | $44.2M | $7.5M | -$31.6M |
| Free cash flow | $126.6M | $63.8M | $34.3M | -$1.0M | -$37.0M |
| Total assets | $1.4B | $1.3B | $1.1B | $1.2B | $1.2B |
| Total liabilities | $96.4M | $124.1M | $70.8M | $81.2M | $91.3M |
| Stockholders' equity | $1.3B | $1.2B | $1.0B | $1.1B | $1.1B |
| Cash and investments | $362.6M | $239.1M | $216.5M | $154.2M | $173.2M |
| Total debt | $39.7M | $50.7M | $12.7M | $15.1M | $19.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Sep 14, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 1003 Veracyte, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.